Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 with Adebrelimab and SHR-8068 in Advanced NSCLC
NCT06589778Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-A2102 in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Primary endpoints: Recommended Phase II Dose at 21 days, Objective Response Rate at 12 months and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06589778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589778.